Ophthalmic Drugs Market Forecast 2016-2026

LONDON, July 20, 2016 /PRNewswire/ --

Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs

What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.
 
Our 334-page report provides 238 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs 

To see a report overview please email Sara Peerun on [email protected]

The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju 

The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Avastin
• Visudyne
• Jetrea
• Pataday
• Vigamox
• Patanol
• TobraDex
• Cravit
• AzaSite
• Acular
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Azopt
• Trusopt
• Zioptan
• Cosopt
• Tapros/Taflotan
• Restasis
• Refresh
• Hyalein
• Diquas 

Leading companies and potential for market growth
Retinal disorder drugs will remain the leading ophthalmic submarket to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Ophthalmic Drugs Market Forecast 2016-2026 report helps you
In summary, our 334-page report gives you the following knowledge:
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
• Revenue forecasts to 2026 for 25 leading drugs - discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Avastin, Visudyne, Jetrea, Pataday, Vigamox, Patanol, TobraDex, Cravit, AzaSite, Acular, Lumigan and Ganfort, Xalatan/Xalacom, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Azopt, Trusopt, Zioptan, Cosopt, Tapros/Taflotan, Restasis, Refresh, Hyalein and Diquas
• Revenue forecasts to 2026 for the 9 leading companies in the market - discover the industry's prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer and Senju
• Assessment of 50 pipeline products - analysis of clinical trial progress and drug candidate potential across all ophthalmic indications
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1690/Ophthalmic-Drugs-Market-Forecast-2016-2026

Companies Mentioned in the Report 

Acucela

Actavis

Advanced Cell Technologies

Aerie Pharmaceuticals

Aerpio Therapeutics

Alcon

Alembic

Algeta

Alimera Sciences

Allegro

Allergan

Akorn

Amakem

Amgen

Ampio Pharmaceuticals

Apotex

Asahi Glass

AstraZeneca

Aurobindo Pharma Ltd

Aventis

Barr Laboratories

Bausch & Lomb

Biocad

BioDiem

Biovail Corporation

BioXpress Therapeutics

Bristol-Myers Squibb

Can-Fite BioPharma

Cipla

Chengdu Kanghong Pharmaceutical

Chiesi Farmaceutici S.p.A

Chiron Corporation

Chugai Pharmaceutical

CIBA VISION

Colby Pharmaceuticals

Daiichi Sankyo

Eleven Biotherapeutics

Eli Lilly

ESBATech

EyeCyte

EyeGate

Eyetech Pharmaceuticals

ForeSight Biotherapeutics

ForSight VISION4

Fougera Pharmaceuticals

Gene Signal

Genentech

GlaxoSmithKline

Hospira

iCo Therapeutics

Icon Bioscience

InSite Vision

Inspire Pharmaceuticals

Instituto Terapeutico Delta Ltda

Jenapharm

Johnson & Johnson

Kala Pharmaceuticals

KalVista

Kestrel Ophthalmics

Kyorin Pharmaceutical

Kyowa Hakko Kirin

LEO Pharma

Lpath

MacuCLEAR

MacuSight

MAP Pharmaceuticals

MEAgate International FZLLC

Meda

Merck & Co. (Merck)

MerLion

Molecular Partners

MSD K.K.

Neurim Pharmaceuticals

Neurotech

NovaBay

Novagali

Novartis

Novel Labs Inc

OHR Pharmaceutical

Omeros

OphthaliX

Ophthotech

PanOptica

Patheon Pharmaceuticals

Par Pharmaceutical

Pfizer

Pharmacia

PreCision Dermatology

Procter & Gamble

pSivida

QLT

Quark Pharmaceuticals

Regeneron

Reckitt Benckiser

Roche

Roche Consumer Health

R-Tech Ueno

RXi Pharmaceuticals

Salix

Sanofi

Sandoz

Santaris Pharma

Santen

Schering AG

Seikagaku

Senju

Servier

Shire

SkinMedica

Sobi

Stelgerwald

Spark Therapeutics

Takeda

ThromboGenics

Upjohn

UV North America

Valeant

Vanda Pharmaceuticals

Ventana Medical Systems

Warburg Pincus LLC

Watson

Wockhardt

Wyeth Pharmaceuticals

Zach System Spa

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd